Review of available intravenous iron preparations in hemodialysis.
University Health Network, Toronto, ON.
Katie
K
Palmer
Karen
K
Cameron
Marisa
M
Battistella
D018798:Anemia, Iron-Deficiency / Q000209:etiology / Q000517:prevention & control*; D002170:Canada; D005290:Ferric Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000077605:Ferric Oxide, Saccharated; D052203:Ferrosoferric Oxide / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D005937:Glucaric Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007505:Iron-Dextran Complex / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D006435:Renal Dialysis / Q000009:adverse effects* / Q000451:nursing
D005290:Ferric Compounds; D006397:Hematinics; D007505:Iron-Dextran Complex; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; C035552:ferric gluconate; D052203:Ferrosoferric Oxide